Advertisement

Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lixte Biotechnology has signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and NCI.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy. 
Advertisement
Advertisement